{
    "other_tests": [
        {
            "procedure_name": "HbA1c",
            "date": "Not specified",
            "findings": "HbA1c was 6.7%, increased from 6.4% at the last office visit with his pediatric endocrinologist 3 months prior.",
            "changes_over_time": "The HbA1c rose from 6.4% to 6.7% over three months."
        },
        {
            "procedure_name": "C-peptide",
            "date": "Not specified",
            "findings": "The C-peptide was 1.2 ng/mL (reference 0.8 - 3.2 ng/mL), indicating evidence of residual β-cell function.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Urinary C-peptide to creatinine ratio (UCPCR)",
            "date": "Not specified",
            "findings": "2-hour post-prandial UCPCR of > 0.2 nmol/mmol was reported.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Genetic testing (multigene panel)",
            "date": "Not specified",
            "findings": "Revealed a pathogenic mutation in HNF4A (c.790: del ‘G’ resulting in p.Val264Cys frameshift mutation).",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Follow-up screening for complications",
            "date": "Not specified",
            "findings": "Lipid panel demonstrated total cholesterol of 137 mg/dL, HDL of 25 mg/dL, LDL of 76 mg/dL, and triglyceride level of 182 mg/dL. His dilated retinal examination did not demonstrate retinopathy, and the urine albumin to creatinine ratio was 17 mg/g.",
            "changes_over_time": "The patient has remained on monotherapy with once weekly semaglutide treatment for more than one year with HbA1c < 6.5% and without notable side effects or complications."
        }
    ]
}